On December 7, 2021 Persephone Biosciences Inc. ("Persephone"), a privately held company investigating the human microbial ecosystem’s effect on therapeutic treatment, diagnostics and disease prevention, reported a collaboration with Janssen Research & Development, LLC, (Janssen) for the colorectal cancer (CRC) arm of Persephone’s ARGONAUT study (Press release, Janssen Research & Development, DEC 7, 2021, View Source [SID1234596580]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
ARGONAUT is a longitudinal, prospective, observational study that will collect and analyze stool and blood samples from 4,000 advanced-stage cancer patients and healthy individuals with varying cancer risk, of diverse racial backgrounds. The data collected can be used to develop precision microbiome medicines and for the identification of clinically actionable cancer-specific biomarkers to guide therapeutic decisions.
ARGONAUT will profile four types of solid tumor cancers: non-small cell lung cancer (NSCLC), triple negative breast cancer (TNBC), colorectal cancer (CRC) and pancreatic cancer. Through the agreement announced today, Persephone will work with Janssen on the CRC patient arm and additional healthy individuals with varying cancer risk enrolled in the study. Financial terms related to the agreement are not being disclosed. Persephone intends to sign additional agreements covering the study’s other arms.
The results of the ARGONAUT study could provide a better understanding of the gut microbiome’s role in patient response to cancer therapies, which could in time lead to the development of adjuvant therapeutics or a precision medicine approach to future oncology interventions, based on prior microbiome diagnostic testing. In addition, the potential discovery of biomarkers in the microbiome could enable earlier cancer detection and intervention. Importantly, the ARGONAUT study will enroll a diverse patient population, emphasizing patients from minority groups.
"We are delighted to be working with Janssen in ARGONAUT’s colorectal cancer arm in this important new area of therapeutic research," said Stephanie Culler, CEO and Co-founder of Persephone Biosciences. "Importantly, patient diversity is a key driver of enrollment for the study, and we look forward to curating a study that will encompass a large cross section of American society, with implications for future oncology interventions worldwide."
About ARGONAUT
The official title of the ARGONAUT study is: "Argonaut: Development and Analysis of a Blood, Tissue and Stool Sample Bank for Cancer Patients, Enabling the Systematic Study of Host-Gut Microbiome Interactions on the Response to Colorectal Cancer Treatment, and Analysis of Biomarkers of Cancer Risk." More information can be found at www.clinicaltrials.gov using the identifier NCT04638751.